📋 Tender Overview
This completes the first phase of the project in which a 600 m2 bioanalytical laboratory was equipped with leading instrumentation and equipment including a Watson LIMS system and WinNonlin software. The second phase will include the completion of a biosafety level 2 BSL-2 laboratory which will be ready in Q3 2022.The GLP-compliant laboratory follows ICH NMPA FDA and EMA principles. Its expert staff can design test plans tailored to customers needs carry out biological sample analysis and provide comprehensive data analysis reports.SGS is now well placed to serve the bioanalytical needs of organizations in the region whether they are engaged in preclinical or clinical trials. By working with SGSs Shanghai laboratory organizations can not only gather critical data but can also reduce costs submit successful drug declarations and ultimately get their products to market quickly and safely.Michael Lindsay Global Scientific Director said The Chinese drug development market is booming. Thanks to the opening of our new bioanalytical laboratory SGS is set to play a key role in supporting local and global pharmaceutical and biopharmaceutical drug development.Advantages of Using SGSs Shanghai Bioanalytical LaboratoryHarmonized processes with existing global bioanalytical servicesAccess to local experts expediting the drug development processReports can be used for multinational declarationsAn exceptional team with bioanalytical experience in studying liposomes albumin binding proteins peptides small nucleic and poly-nucleic acids and endogenous biomarkers including cytokinesIndustry-leading equipment and systems including API 6500 Plus UPLC MESOTM Sector S600 and MD SpectraMax M5 systems a Watson LIMS platform and a GLP quality systemWai Lam Health Science Director SGS China commented This new state-of-the-art facility backed up by SGSs global network of laboratories will be at the forefront of bioanalytical testing in China. Our scientific experts cant wait to get started.
